Oncotelic Opens PDAOAI BIO REBOOT Collaboration

Oncotelic Therapeutics, Inc., together with its wholly owned subsidiary Pet2DAO, Inc., announced that PDAOAI is opening the BIO REBOOT collaboration, according to Yahoo News. The announcement also said PDAOAI will showcase partitioned literature aggregation at Drug Discovery 2026.

Yahoo News identified PDAOAI as Oncotelic’s AI-powered drug discovery platform. The company said the platform is inviting scientists, AI developers and biotech founders to connect computational discovery with drug development.

BIO REBOOT collaboration opens

According to Yahoo News, the BIO REBOOT collaboration is being opened through PDAOAI. Oncotelic and Pet2DAO named scientists, AI developers and biotech founders as the groups invited to connect computational discovery with drug development.

The announcement places PDAOAI at the center of the collaboration. Oncotelic described the platform as AI-powered and focused on drug discovery, while the stated invitation connects computational discovery and drug development.

For pharmaceutical and biotech sales professionals, the update identifies a collaboration initiative involving scientific, technology and biotech audiences. The named participants reflect the announcement’s focus on bringing together groups associated with computational discovery and drug development.

Partitioned literature aggregation at Drug Discovery 2026

Yahoo News reported that PDAOAI is showcasing partitioned literature aggregation at Drug Discovery 2026. The capability was included alongside the BIO REBOOT collaboration announcement.

Oncotelic’s announcement identifies partitioned literature aggregation as part of the PDAOAI showcase. Yahoo News reported the event name as Drug Discovery 2026 and described PDAOAI as the company’s AI-powered drug discovery platform.

The update combines a collaboration invitation with a platform showcase. Oncotelic and Pet2DAO are the companies named in the announcement, while PDAOAI is the platform through which the collaboration and showcase are presented.

Organizations and audiences named

• Oncotelic Therapeutics, Inc.
• Pet2DAO, Inc.
• PDAOAI
• Scientists
• AI developers
• Biotech founders

Yahoo News reported that the companies’ announcement centers on connecting computational discovery with drug development, alongside PDAOAI’s partitioned literature aggregation showcase at Drug Discovery 2026.